Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1-2 Trial for Patients With Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells

NCT01660607 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT01660607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01660607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1-2 Trial for Patients With Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells
Lead sponsor
Stanford University
Phase
Phase 1/2
Overall status
Completed
Start date
February 9, 2012
Completion date
December 20, 2023
Enrollment
68 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, acute lymphoblastic leukemia (all), acute myelogenous leukemia, acute myeloid leukemia, chronic myelogenous leukemia, lymphoma, non-hodgkin, myelodysplastic syndromes (mds), myeloid leukemia, chronic, myeloproliferative syndrome